Novartis to profit from pharmaceutical merger

With a carefully calculated merger, healthy financial indicators and the support of a local manufacturer, the newly-formed pharmaceutical company, Novartis Pharma Services is seeking to become the king of Slovakia's competitive market.
Created by the merger of Sandoz and CIBA, Novartis is involved in pharmaceutical products, health care and contact lenses; agribusiness, which includes crop protection, animal health and seeds; and nutrition.
At the June 24 press conference officially introducing Novartis, Henning Remmer, the company's general manager, said, "In the Slovak Republic, CIBA and Sandoz have been active for many years. We are aiming at creating a new company based on the best philosophies and best practices from the two former companies."

With a carefully calculated merger, healthy financial indicators and the support of a local manufacturer, the newly-formed pharmaceutical company, Novartis Pharma Services is seeking to become the king of Slovakia's competitive market.

Created by the merger of Sandoz and CIBA, Novartis is involved in pharmaceutical products, health care and contact lenses; agribusiness, which includes crop protection, animal health and seeds; and nutrition.

At the June 24 press conference officially introducing Novartis, Henning Remmer, the company's general manager, said, "In the Slovak Republic, CIBA and Sandoz have been active for many years. We are aiming at creating a new company based on the best philosophies and best practices from the two former companies."

According to Remmer, Novartis aims to become the number one pharmaceutical company worldwide, a position they now share with Glaxo. Remmer added, "In the Slovak Republic, as I know the figures, we are the biggest international pharmaceutical company in the market."

Novartis does not, at least on a global basis, see Slovakofarma or other Slovak companies as their direct competitors. In fact, Slovakofarma manufactures several products for Novartis for the Slovak market.

Oriol Ros, the head country liaison for medicine, pointed out that Novartis, in essence, tied for number one in market share with Glaxo at 4.4 percent in 1995 and 1996. Hoechst, Bristol-Meyers, and American Home Products all trail in market share.

Outlining Novartis's strategy, Ros stated, "Two years ago, Novartis - CIBA at the time - started considering the possibility that if you want to have a leading position in the pharmaceutical sector, you need to have a big market share. And with less than three percent two years ago, this was impossible. The merger [allowed us to have] what we call a minimum critical mass and this minimum critical mass allows us to stay in first place with Glaxo."

According to a recent report from the independent analyst Merrill Lynch, projected sales figures for Novartis from 1996 to 2000 indicate an increase of 7.9 percent per year. The report also indicated that profit is expected to increase by 15.9 percent and, even more importantly, the return on sales are projected at a hefty 10 percent increase.

The total sales for the company for 1996 stands at 27 billion Swiss francs, 16 percent of which was invested in research and development, similar to its competitors.

When questioned about the amount spent on research and development, Remmer stated, "It is one of our favorite topics because we know that with spendings of about 2.4 billion Swiss francs, we are the number one spending research company. We have big hopes for the future that these investments in research will also bring out products that are needed for the future. And that is our number one aim. This is a long-term investment for six to eight years from now." Current plans call for 29 launches of new products in the next three years.

The processing of personal data is subject to our Privacy Policy and the Cookie Policy. Before submitting your e-mail address, please make sure to acquaint yourself with these documents.

Top stories

Prosecution of OL'aNO member has been delayed for months but witnesses have already testified

Security analyst Jaroslav Naď provoked the investigation with questions about Russian spies at the embassy.

Jaroslav Naď

Another woman found dead in Bratislava

Police say there is no connection with the murder of an English teacher.

An illustrative photo

Traditional Charity Christmas Bazaar returns to Stará Tržnica

The Bazaar provides a unique opportunity for countries to introduce themselves to the local community.

Christmas Bazaar 2008, Old Market Hall

It matters when two bishops speak up against Kuffa

“Clero-fascism” is more than just a textbook term in Slovakia.